BU-NOT-SET
A forward-thinking approach to effective product development
Transform your early-stage concepts into supply for all clinical phases with a partner you can trust.
We deliver tailored, drug substance and drug product, development solutions for small and large molecules combining deep scientific ingenuity and a seamlessly integrated global network to help you overcome complexity, de-risk your programme and confidently scale your molecule for commercial success.
Predictive development, fewer surprises
Our development services are built around a quality-by-design (QbD) approach, shaping formulation and process parameters from the outset to support reliable performance and manufacturability. Designed for API-constrained programmes, our small-scale studies assess performance under manufacturing-relevant conditions to minimise trial and error.
Our development services
Every molecule requires a bespoke strategy. Our core development services are fully adaptable to the unique demands of your programme, delivering the precise technical expertise required at every phase.
● Formulation development
● Process development (NCE and generics)
● Analytical method development
● Reformulation
Dosage forms we support
With expertise across a comprehensive range of dosage forms, our development scientists design formulations adapted to each phase of the product development, optimised for patient compliance, bioavailability and commercial scale-up.
● Solids
● Semi-solids and liquids
● Sterile products
● Oral biologics/oral enzymes
Why partner with Recipharm
Powered by ReciPredict, we align formulation, analytical and process development from early development to clinic. This integrated, predictive approach replaces traditional trial-and-error with data-driven design, delivering robust, scalable outcomes that set your programme up for commercial success.
● Accelerated development timelines: Streamlined workflows and reduced physical iterations through data-driven design.
● Reduced API consumption: In silico modelling and material-sparing techniques during early phases.
● Solutions for complex formulations: Deep scientific ingenuity and predictive insights.
● Comprehensive design-space understanding: Advanced modelling and robust analytics to thoroughly characterise and optimise your product.
● De-risked scale-up and tech-transfer: Inherently scalable processes from the onset, relying on early, predictive process understanding.
The Recipharm assurance
Count on us to help you minimise complexity at every stage of your product development journey.
FAQs
We combine formulation expertise, predictive tools and studies to address challenges such as poor solubility, stability and manufacturability. By assessing material properties and performance early, we design formulations that are robust, patient-focused and suitable for scale-up.
Yes. Recipharm provides integrated support across the full product lifecycle, from early formulation development and clinical supply through to scale-up, tech-transfer and commercial manufacturing. Our global network and scalable technologies help ensure a seamless transition at every phase
We consider manufacturability from the outset, aligning formulation, analytical and process development early in the programme. Using QbD principles and small-scale studies under manufacturing-relevant conditions, we build process understanding that supports reliable scale-up, tech transfer and commercial manufacturing.
We apply QbD principles from the outset, defining formulation and process parameters early to support quality, performance and manufacturability. Using predictive modelling and data-driven design, we build robust process understanding while reducing development risk and unnecessary iteration.
Development timelines can be accelerated through early process understanding and informed decision-making. Using predictive development approaches, QbD principles and small-scale studies under manufacturing-relevant conditions, we generate the data needed to support efficient development and reduce the risk of delays later in the programme.
Risks identified during early development can have a significant impact on scale-up, tech-transfer and manufacturing. Common challenges include limited process understanding, formulation constraints and material variability. Our predictive development approach helps identify and address these risks early, supporting more reliable progression through development.
Reducing time-to-market starts with building manufacturing considerations into development from the outset. By aligning formulation, analytical and process development activities early, and generating insight into future manufacturing performance, we help minimise delays and support efficient progression towards clinical and commercial manufacturing.
Our analytical and formulation teams work in parallel from the start of development, creating aligned strategies that support faster decision-making and stronger process understanding. This integrated approach helps identify risks early, streamline development and support scalable, commercially viable outcomes.
